ENTYVIO- vedolizumab injection, powder, lyophilized, for solutionENTYVIO PEN- vedolizumab injection, solutionENTYVIO- vedolizumab injection, solutionTakeda Pharmaceuticals America, Inc.
1 INDICATIONS AND USAGEENTYVIO is indicated in adults for the treatment of:
moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn’s disease (CD). 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration InformationBefore initiating ENTYVIO, update immunizations according to current immunization guidelines [see Warnings and Precautions (5.5)].
Intrenous Administration
ENTYVIO should be administered by a healthcare provider prepared to manage hypersensitivity reactions including anaphylaxis, if they occur [see Warnings and Precautions (5.1)]. Appropriate monitoring and medical support measures should be ailable for immediate use. Observe patients during infusion and until the infusion is complete. Reconstitute and dilute ENTYVIO lyophilized powder prior to administration as a 30-minute intrenous infusion [see Dosage and Administration (2.3)]. Subcutaneous Injection
ENTYVIO prefilled syringe and ENTYVIO PEN are intended for subcutaneous use under the guidance and supervision of a healthcare professional. Patients may self-inject or caregivers may inject subcutaneous ENTYVIO using either the ENTYVIO prefilled syringe or ENTYVIO PEN after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of ENTYVIO. 2.2 Recommended Dosage in Adults with Ulcerative Colitis and Crohn’s Disease Week 0: Administer ENTYVIO 300 mg by intrenous infusion over approximately 30 minutes [see Dosage and Administration (2.3)]. Week 2: Administer ENTYVIO 300 mg by intrenous infusion over approximately 30 minutes. Week 6: Patients may remain on ENTYVIO intrenous therapy or switch to subcutaneous injection after receiving two ENTYVIO intrenous doses administered at Week 0 and Week 2. Intrenous Infusion: Administer ENTYVIO 300 mg by intrenous infusion over approximately 30 minutes and then every eight weeks thereafter. Subcutaneous Injection: Administer ENTYVIO 108 mg subcutaneously once every 2 weeks. Discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14. Patients currently receiving and responding to ENTYVIO intrenous therapy after Week 6 may also be switched to subcutaneous injection. Administer the first subcutaneous dose in place of the next scheduled intrenous infusion and every two weeks thereafter.
2.3 Preparation and Administration Instructions for Intrenous InfusionReconstitution Instructions
Remove the flip-off cap from the single-dose vial and wipe with alcohol swab. Reconstitute ENTYVIO vial containing lyophilized powder with 4.8 mL of Sterile Water for injection, 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, at room temperature (20°C to 25°C [68ºF to 77ºF]), using a syringe with a 21- to 25-gauge needle. Insert the syringe needle into the vial through the center of the stopper and direct the stream of Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, to the glass wall of the vial to oid excessive foaming. Gently swirl the vial for at least 15 seconds to dissolve the lyophilized powder. Do not vigorously shake or invert. Allow the solution to sit for up to 20 minutes at room temperature to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution. Do not use the vial if the drug product is not dissolved within 30 minutes. Visually inspect the reconstituted ENTYVIO solution for particulate matter and discoloration prior to dilution. Solution should be clear or opalescent, colorless to light brownish yellow and free of visible particulates. Do not administer reconstituted solution showing uncharacteristic color or containing particulates. Once dissolved, gently invert vial three times. Immediately, withdraw 5 mL (300 mg) of reconstituted ENTYVIO solution using a syringe with a 21- to 25-gauge needle. Discard any remaining portion of the reconstituted solution in the vial.Dilution Instructions
Add the 5 mL (300 mg) of reconstituted ENTYVIO solution to 250 mL of 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, and gently mix the infusion bag. Do not add other medicinal products to the prepared infusion solution or intrenous infusion set. Once reconstituted and diluted, use the infusion solution as soon as possible.
Discard any unused portion of the infusion solution.
Administration Instructions
After the infusion is complete, flush with 30 mL of 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection.
Storage and Stability
Specific storage conditions and timing for the reconstituted solution in vial and diluted solution in the infusion bag are outlined in Table 1.
Do not freeze the reconstituted solution in the vial or the diluted solution in the infusion bag.
Table 1. Storage Instructions for Reconstituted Solution in Vial and Diluted Solution in Infusion Bag Solution Storage Conditions Refrigeration(2°C to 8°C [36°F to 46°F]) Room Temperature(20°C to 25°C [68°F to 77°F]) * This time assumes the reconstituted solution is immediately diluted in the 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, and held in the infusion bag only. Any time that the reconstituted solution was held in vial should be subtracted from the time the solution may be held in the infusion bag. † This period may include up to 12 hours at room temperature (20°C to 25°C [68°F to 77°F]). Reconstituted Solution (in Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer’s Injection, inside vial) 8 hours Use immediately after reconstitution Diluted Solution (in 0.9% Sodium Chloride Injection) 24 hours *, † 12 hours * Diluted Solution (in Lactated Ringer’s Injection) 6 hours * Use immediately after dilutionThe combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with 0.9% Sodium Chloride Injection, is a total of 12 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours refrigerated (2°C to 8°C [36°F to 46°F]). This combined storage time may include up to eight hours of the reconstituted solution in the vial at 2°C to 8°C.
The combined storage time of reconstituted ENTYVIO solution in the vial and the diluted solution in the infusion bag with Lactated Ringer’s Injection, is a total of six hours refrigerated (2°C to 8°C [36°F to 46°F]).
Page 1 of 9 1 2 3 4 5 … » Last Page » Also by this Manufacturer Additional medications in the ‘Prescription Medications’ section by Takeda Pharmaceuticals America, Inc. Or get Takeda Pharmaceuticals America, Inc. product information by RSS. Related SearchesWithin the ‘Prescription Medications’ section:
Brand names beginning with the letter ‘E’ (Entyvio). Medications with generic name beginning with the letter ‘V’ (Vedolizumab). Medication information from June 2024, newest first or June 2024, earliest first.All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/entyvio/